Carriero M V, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli M P, Salvatore M
Istituto Nazionale Tumori, Napoli, Italy.
Cancer Res. 1994 Oct 15;54(20):5445-54.
Current evidence regarding the regulation of urokinase-dependent extracellular proteolysis indicates that plasminogen activation is a surface-associated process. We have compared the histological localization of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) in breast cancer sections using a panel of monoclonal antibodies. First, the ability of six different anti-uPA monoclonal antibodies to recognize pro-uPA, uPA, and in vitro-formed complexes of uPA with either soluble uPAR or with plasminogen activator inhibitor type 1 was compared. Then the reactivity of the anti-uPAR antibodies was tested, and the occurrence of an uPA receptor of about M(r) 55,000 in samples from breast carcinoma was assessed by immunoprecipitating the uPA receptor from an in vitro 125I-labeled tumor extract. Immunocytochemical data from adjacent sections of 10 tumor specimens showed that antibodies recognizing free and bound uPA mostly stain the cytoplasm and the membrane of epithelial tumor cells in confined areas of the tumor and some fibroblast-like stromal cells. Acid pretreatment of tumor sections, which removes receptor-bound uPA, causes a strong reduction of the immunocytochemical reactivity of epithelial tumor cells, whereas staining of fibroblast-like cells is not considerably affected. Consistent with these results, epithelial tumor cells were mostly unreactive to anti-uPAR antibodies unless pretreated with acidic buffer, whereas fibroblast-like stromal cells showed a faint but acid-resistant staining with all anti-uPARs. In conclusion, these results show that occupied uPA receptors are definitely present on the membrane of epithelial tumor cells and suggest the occurrence of uPA-uPAR-dependent proteolytic activity on the surface of breast cancer cells.
目前有关尿激酶依赖性细胞外蛋白水解调节的证据表明,纤溶酶原激活是一个与表面相关的过程。我们使用一组单克隆抗体比较了乳腺癌切片中尿激酶型纤溶酶原激活剂(uPA)和尿激酶型纤溶酶原激活剂受体(uPAR)的组织学定位。首先,比较了六种不同的抗uPA单克隆抗体识别pro-uPA、uPA以及uPA与可溶性uPAR或1型纤溶酶原激活剂抑制剂体外形成复合物的能力。然后测试了抗uPAR抗体的反应性,并通过从体外125I标记的肿瘤提取物中免疫沉淀uPA受体,评估了乳腺癌样本中约55,000 M(r)的uPA受体的存在情况。来自10个肿瘤标本相邻切片的免疫细胞化学数据显示,识别游离和结合uPA的抗体大多在肿瘤的局限区域内染上皮肿瘤细胞的细胞质和膜以及一些成纤维细胞样基质细胞。对肿瘤切片进行酸预处理可去除受体结合的uPA,导致上皮肿瘤细胞的免疫细胞化学反应性大幅降低,而成纤维细胞样细胞的染色则未受到明显影响。与这些结果一致,上皮肿瘤细胞除非用酸性缓冲液预处理,否则对抗uPAR抗体大多无反应,而成纤维细胞样基质细胞对所有抗uPAR均显示微弱但耐酸的染色。总之,这些结果表明上皮肿瘤细胞膜上确实存在被占据的uPA受体,并提示乳腺癌细胞表面存在uPA-uPAR依赖性蛋白水解活性。